AOD-9604: Precision Lipolysis Without Growth Effects

Background

AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone (hGH), specifically residues 177–191. Development was motivated by a specific research question: can the lipolytic activity of hGH be separated from its broader anabolic, IGF-1-generating, and glucose-affecting activities? If so, the resulting fragment would be a far more precise research tool for studying adipose biology than full-length GH.

AOD-9604 is the molecule that answered yes — at least in terms of research pharmacology. It produces adipose-directed effects without measurable activation of the growth hormone receptor in standard assays.

Molecular profile

• Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 aa)
• Modification: N-terminal tyrosine added to native hGH(177-191); disulfide bond between Cys-7 and Cys-14
• Molecular weight: ~1,817 Da
• CAS: 221231-10-3
• Developer: Monash University / Metabolic Pharmaceuticals (Australia)

Mechanism: adipose-selective lipolysis

Unlike full hGH — which acts through the growth hormone receptor (GHR), a dimerizing cytokine-family receptor that activates JAK2/STAT5 signaling and drives hepatic IGF-1 generation — AOD-9604 appears to work through distinct pathways:

• No measurable GHR activation in standard reporter assays at pharmacologically relevant concentrations
• No IGF-1 elevation in published studies — a critical distinction from full hGH
• No significant glucose-level perturbation — unlike hGH, which induces insulin resistance at higher doses
• Hormone-sensitive lipase (HSL) activation — promotes triglyceride breakdown in adipocytes
• β3-adrenergic receptor upregulation — increases receptor density and response to catecholamines
• Inhibition of lipogenesis — reduces fatty acid synthesis in parallel with promoting breakdown
• Proposed distinct receptor — some research suggests a fat-specific receptor or mechanism, though the identity remains a subject of investigation

What laboratories typically study

• Adipocyte lipolysis assays — free fatty acid (glycerol) release from 3T3-L1 or primary adipocytes
• HSL activity — phosphorylated HSL immunoblots, enzymatic activity assays
• Adipogenesis — preadipocyte differentiation, lipid droplet accumulation (Oil Red O staining)
• Lipogenic gene expression — FAS (fatty acid synthase), ACC (acetyl-CoA carboxylase), SREBP1c
• β-adrenergic biology — receptor density by radioligand binding, cAMP response to catecholamines
• DIO rodent models — adipose tissue characterization, body composition, metabolic parameters
• Head-to-head vs hGH — demonstrating lipolysis-specific effect without IGF-1 elevation
• Cartilage research — some studies explore AOD-9604 effects on chondrocyte biology independent of systemic GH axis

What AOD-9604 is not

Given marketing claims sometimes found in non-research contexts, clarification is useful:

• Not equivalent to hGH — lacks anabolic and IGF-1-generating effects
• Not a GH secretagogue — does not stimulate pituitary GH release
• Not a myostatin inhibitor
• Not a systemic anabolic agent — research data specifically shows absence of growth-promoting effects

Its research value is precisely its adipose selectivity.

Handling and quality

• Supplied as lyophilized powder (typical research format 5 mg)
• Store lyophilized at -20°C, protected from light
• Reconstitute with sterile/bacteriostatic water
• Disulfide bond integrity is important — avoid harsh reducing conditions during reconstitution
• Reconstituted solution stable ~4 weeks at 2–8°C
• Verify by HPLC (≥99.0%) with MS identity confirmation; request batch COA

Related reading

• /research/aod-9604 — compound profile
• /blog/aod-9604-vs-hgh-fragment-lipolysis-research — fragment comparison
• /category/weight-loss-research — broader category
• /guides/how-to-read-peptide-coa — batch documentation

RUO disclaimer

For laboratory research use only. Not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption outside approved research settings.